Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT05135793 Completed - Healthy Clinical Trials

Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)

Start date: January 19, 2021
Phase: Phase 1
Study type: Interventional

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)

NCT ID: NCT05132049 Completed - Healthy Clinical Trials

Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers

Start date: December 18, 2021
Phase: Phase 1
Study type: Interventional

Pharmacokinetics and safety Profiles after administration of DA-5211 and co-administration of DA-5211-R1 and DA-5211-R2 in healthy adult volunteers

NCT ID: NCT05132023 Completed - Healthy Clinical Trials

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Start date: March 26, 2019
Phase: Phase 1
Study type: Interventional

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Empagliflozin & Metformin HCL from Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

NCT ID: NCT05128058 Completed - Healthy Clinical Trials

A Target Occupancy Study With Ritlecitinib.

Start date: October 22, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, open label, two-arm study to assess target occupancy and functional inhibition of JAK3 and TEC kinases by Ritlecitinib in healthy adult participants

NCT ID: NCT05127746 Completed - Healthy Clinical Trials

Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Start date: November 25, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

NCT ID: NCT05123911 Completed - Healthy Clinical Trials

A Study of 3 Investigational Products on the Microbiome and Scalp Attributes in Children With Curly Hair

Start date: November 13, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the topical safety (tolerability/acceptability) of a kit of cosmetic products (shampoo, conditioner, and combing cream), the presence of residues on the scalp through visual assessment and image capture, the skin barrier, pH, and sebum level. All these evaluations will be performed before and after 28 plus minus (+-) 2 days of use under normal conditions, under the supervision of dermatologist and pediatrician.

NCT ID: NCT05123820 Completed - Healthy Clinical Trials

Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470

Start date: November 13, 2021
Phase: Phase 1
Study type: Interventional

A study on whether ACT-1014-6470 has an effect on how the body takes up, distributes and gets rid of omeprazole and midazolam in healthy male subjects

NCT ID: NCT05123079 Completed - Healthy Clinical Trials

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

Start date: November 2, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-center trial in healthy participants. This is a crossover design, open-label treatment trial with 3 periods, 6 sequences.

NCT ID: NCT05121714 Completed - Healthy Clinical Trials

Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

Start date: December 17, 2020
Phase: Phase 1
Study type: Interventional

A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs

NCT ID: NCT05120115 Completed - Healthy Clinical Trials

Optimization of Hip-exoskeleton Weight Attributes

Start date: October 7, 2021
Phase: N/A
Study type: Interventional

The investigators are examining how weight distribution affects the way people walk, in terms of joint kinematics, kinetics, and muscle activity. The investigators are measuring these quantities while people walk while wearing a weighted belt. The investigators distribute the weights and walk for specified periods. They hypothesize that greater weight will have a greater effect on walking.